Take Homes in Multiple Myeloma

Take Homes in Multiple Myeloma

Source:

Nishihori T, et al. Abstract 7003. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Gasparetto reports leadership fees from Celgene; consulting/advising for AbbVie/Genentech, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi; speakers’ fees from GlaxoSmithKlinem Karyopharm Therapeutics, Sanofi; and travel expenses from Celgene and Karyopharm Therapeutics
June 24, 2021
1 min watch
Save

VIDEO: Allogeneic transplant shows potential in high-risk multiple myeloma

Source:

Nishihori T, et al. Abstract 7003. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Gasparetto reports leadership fees from Celgene; consulting/advising for AbbVie/Genentech, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi; speakers’ fees from GlaxoSmithKlinem Karyopharm Therapeutics, Sanofi; and travel expenses from Celgene and Karyopharm Therapeutics
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Allogeneic hematopoietic cell transplantation showed potential in patients with high-risk multiple myeloma, according to findings presented at the ASCO Annual Meeting.

Allogeneic hematopoietic cell transplantation has always been “a very difficult topic” in multiple myeloma, but the approach may be “more feasible” for younger patients with very aggressive disease in certain situations, Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, told Healio in a video interview.

“We were pleasantly surprised by the favorable outcome in this difficult population of patients,” Gasparetto said. “The transplant related mortality always has been a barrier to proceed with allogenic transplant in this population of patients, but the transplant-related mortality was actually very low – around 5%.”